As of 2025-06-20, the Relative Valuation of Kalvista Pharmaceuticals Inc (KALV) is (60.63) USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.31 USD, the upside of Kalvista Pharmaceuticals Inc based on Relative Valuation is -592.5%.
The range of the Relative Valuation is (40.26) - (81.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 26.0x | 19.2x |
| Forward P/E multiples | 12.8x - 26.0x | 19.4x |
| Fair Price | (40.26) - (81.78) | (60.63) |
| Upside | -427.1% - -764.3% | -592.5% |
| Date | P/E |
| 2025-06-16 | -4.15 |
| 2025-06-13 | -4.12 |
| 2025-06-12 | -4.16 |
| 2025-06-11 | -4.28 |
| 2025-06-10 | -4.52 |
| 2025-06-09 | -4.69 |
| 2025-06-06 | -4.57 |
| 2025-06-05 | -4.39 |
| 2025-06-04 | -4.30 |
| 2025-06-03 | -4.24 |
| 2025-06-02 | -4.11 |
| 2025-05-30 | -3.75 |
| 2025-05-29 | -3.78 |
| 2025-05-28 | -3.62 |
| 2025-05-27 | -3.57 |
| 2025-05-23 | -3.65 |
| 2025-05-22 | -3.63 |
| 2025-05-21 | -3.77 |
| 2025-05-20 | -3.89 |
| 2025-05-19 | -3.84 |
| 2025-05-16 | -3.79 |
| 2025-05-15 | -3.71 |
| 2025-05-14 | -3.61 |
| 2025-05-13 | -3.70 |
| 2025-05-12 | -3.87 |
| 2025-05-09 | -3.78 |
| 2025-05-08 | -3.88 |
| 2025-05-07 | -3.89 |
| 2025-05-06 | -3.97 |
| 2025-05-05 | -4.16 |
| 2025-05-02 | -4.31 |
| 2025-05-01 | -4.32 |
| 2025-04-30 | -4.38 |
| 2025-04-29 | -4.16 |
| 2025-04-28 | -4.13 |
| 2025-04-25 | -4.13 |
| 2025-04-24 | -4.09 |
| 2025-04-23 | -3.96 |
| 2025-04-22 | -3.91 |
| 2025-04-21 | -3.82 |
| 2025-04-17 | -3.82 |
| 2025-04-16 | -3.73 |
| 2025-04-15 | -3.82 |
| 2025-04-14 | -3.80 |
| 2025-04-11 | -3.65 |
| 2025-04-10 | -3.35 |
| 2025-04-09 | -3.44 |
| 2025-04-08 | -3.28 |
| 2025-04-07 | -3.66 |
| 2025-04-04 | -3.41 |